Showing 7961-7970 of 8178 results for "".
- Botox Reaches 10-Year Milestone in Aestheticshttps://practicaldermatology.com/news/20120416-botox_reaches_10-year_milestone_in_aesthetics/2459824/Allergan, Inc. marked the 10-year anniversary of the FDA approval of Botox Cosmetic (onabotulinumtoxinA) to improve the look of moderate to severe frown lines between the eyebrows in patients age 18-65.In the decade since Botox Cos
- Rosacea Awareness: 16 Million Americans Affected, Stressedhttps://practicaldermatology.com/news/20120402-rosacea_awareness_16_million_americans_affected_stressed/2459829/More than 90 percent of more than 1,200 respondents with rosacea said they suffered some form of physical pain from rosacea, according to a new survey by the National Rosacea Society (NRS). With April designated as Rosacea Awareness Month, the NRS strives to educate the public on the effects of rosa
- Medical Students Not Concerned About Skin Cancershttps://practicaldermatology.com/news/20120326-medical_students_not_concerned_about_skin_cancers/2459831/Medical students understand the causes of skin cancer but may be confused about SPF and sunscreen use, comments in recent focus groups suggest. (Arch Dermatol. 148(3):392-393) Surprisingly, most medical students
- Ulthera Cleared in Mexicohttps://practicaldermatology.com/news/20120320-ulthera_cleared_in_mexico/2459837/Ulthera is now registered in Mexico to market and distribute its ultrasound therapy device, the Ulthera System. In Mexico, the system is now prescribed to produce stimulation in tissues to raise the temperature in a localized manner for aesthetic
- EHR iPad App Now Features Speech Recognitionhttps://practicaldermatology.com/news/20120320-ehr_ipad_app_now_features_speech_recognition/2459838/The EZ DERM EHR iPad app is now powered by the cloud-based Nuance Healthcare 360 | Development Platform. The speech recognition platform provides CPU intensive speech and
- Kythera Initiates Phase 3 trials for Investigational Injectablehttps://practicaldermatology.com/news/20120320-kythera_initiates_phase_3_trials_for_investigational_injectable/2459841/Kythera Biopharmaceuticals has initiated two Phase 3 trials of ATX-101, a first-in-class injectable drug under clinical investigation for the reduction of submental fat. The Phase 3 trials, known as REFINE-1 and REFINE-2 (Randomized Doubl
- Commercialization of MelaFind Now Underwayhttps://practicaldermatology.com/news/20120314-commercialization_of_melafind_now_underway/2459843/MELA Sciences, Inc. (NASDAQ: MELA) this week announced that the company has begun commercialization of MelaFind, as part of a controlled and deliberate launch in the U.S. and in Germany. "We are enthusiastic about the success of our final b
- Syneron to Acquire TransPharma Medicalhttps://practicaldermatology.com/news/20120313-syneron_to_acquire_transpharma_medical/2459847/Syneron Medical Ltd. (NASDAQ: ELOS) has signed a definitive agreement to acquire substantially all the assets of TransPharma Medical Ltd. TransPharma Medical, a specialty pharmaceutical company focused on the development and commercialization of drug-
- Xeomin Injunction Stands; Another Hearing Scheduled for Tomorrowhttps://practicaldermatology.com/news/20120312-xeomin_injunction_stands_another_hearing_scheduled_for_tomorrow/2459848/Handing down his order as promised on Friday, US District Court Judge Andrew J. Guilford imposed a 10-month injunction barring Merz from selling or soliciting purchases of Xeomin®, in the US facial aesthetics market for 10 months. However, Judge Gui
- Cellceutix Files pre-IND Submission for Prurisol for Psoriasishttps://practicaldermatology.com/news/20120312-cellceutix_files_pre-ind_submission_for_prurisol_for_psoriasis/2459849/Cellceutix Corporation (OTCBB: CTIX) filed a pre-IND submission with the FDA for Prurisol (also termed KM-133), a drug in development for treatment of psoriasis. The company is seeking guidance to attain approval for a section 505(b)(2) designa